Lung cancer survival in Norway, 1997-2011: From nihilism to optimism

European Respiratory Journal

Volumn 47, Issue 1, 2016, Pages 275-287

  Nilssen, Yngvar ^a   Strand, Trond Eirik ^a   Fjellbirkeland, Lars ^b,c   Bartnes, Kristian ^d,e   Møller, Bjørn ^a  

^a CANCER REGISTRY OF NORWAY   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^e UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ATTITUDE TO ILLNESS; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; EDUCATIONAL STATUS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INOPERABLE CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; NORWAY; OVERALL SURVIVAL; PATIENT ATTITUDE; POPULATION RESEARCH; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SEX DIFFERENCE; SMOKING HABIT; SOCIAL STATUS; VERY ELDERLY; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; CARCINOMA, LARGE CELL; CARCINOMA, SQUAMOUS CELL; EPIDEMIOLOGY; LUNG NEOPLASMS; LUNG RESECTION; MIDDLE AGED; MORTALITY; PROGNOSIS; REGISTER; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CARCINOMA, LARGE CELL; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NORWAY; PNEUMONECTOMY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE;

EID: 84954290426     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00650-2015     Document Type: Article

References (39)

1. Hakulinen T, Engholm G, Gislum M, et al. Trends in the survival of patients diagnosed with cancers in the respiratory system in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol 2010; 49: 608-623.
2. Coleman MP, Forman D, Bryant H, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): An analysis of population-based cancer registry data. Lancet 2011; 377: 127-138.
3. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: Results of EUROCARE-5-A population-based study. Lancet Oncol 2014; 15: 23-34.
4. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-360.
5. Sagerup CM, Smastuen M, Johannesen TB, et al. Sex-specific trends in lung cancer incidence and survival: A population study of 40,118 cases. Thorax 2011; 66: 301-307.
6. Strand TE, Bartnes K, Rostad H. National trends in lung cancer surgery. Eur J Cardiothorac Surg 2012; 42: 355-358.
7. Birim O, Kappetein AP, van Klaveren RJ, et al. Prognostic factors in non-small cell lung cancer surgery. Eur J Surg Oncol 2006; 32: 12-23.
8. Powell HA, Tata LJ, Baldwin DR, et al. Early mortality after surgical resection for lung cancer: An analysis of the English National Lung cancer audit. Thorax 2013; 68: 826-834.
9. Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: Age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol 2002; 13: 1087-1093.
10. Forrest LF, White M, Rubin G, et al. The role of patient, tumour and system factors in socioeconomic inequalities in lung cancer treatment: Population-based study. Br J Cancer 2014; 111: 608-618.
11. Sagerup CM, Smastuen M, Johannesen TB, et al. Increasing age and carcinoma not otherwise specified: A 20-year population study of 40,118 lung cancer patients. J Thorac Oncol 2012; 7: 57-63.
12. Chambers SK, Dunn J, Occhipinti S, et al. A systematic review of the impact of stigma and nihilism on lung cancer outcomes. BMC Cancer 2012; 12: 184.
13. Rostad H, Naalsund A, Norstein J, et al. Er behandlingen av lungekreft i Norge god nok [Is the treatment of lung cancer in Norway adequate]. Tidsskr Nor Laegeforen 2002; 122: 2258-2262.
14. Bremnes RM, von Plessen C, Sundstrom S. Lungekreft-mer aktuelt enn noen gang [Lung cancer-of more current interest than before]. Tidsskr Nor Laegeforen 2006; 126: 1940.
15. Leira HO. Mye lungekreft-lite forskning [Much lung cancer-little research]. Tidsskr Nor Laegeforen 2014; 134: 2287-2288.
16. Larsen IK, Smastuen M, Johannesen TB, et al. Data quality at the Cancer Registry of Norway: An overview of comparability, completeness, validity and timeliness. Eur J Cancer 2009; 45: 1218-1231.
17. US Department of Health and Human Services. SEER program: Comparative staging guide for cancer. Bethesda, US Department of Health and Human Services, 1993.
18. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th Edn. Toronto, Wiley-Blackwell, 2009.
19. Parkin DM, Whelan SL, Ferlay J, et al. Cancer indidence in five continents, vol. VIII. Lyon, International Agency for Research on Cancer, 2002.
20. Nilssen Y, Strand TE, Wiik R, et al. Utilizing national patient-register data to control for comorbidity in prognostic studies. Clin Epidemiol 2014; 6: 395-404.
21. Asli LM, Kvaloy SO, Jetne V, et al. Utilization of radiation therapy in Norway after the implementation of the national cancer plan-A national, population-based study. Int J Radiat Oncol Biol Phys 2014; 90: 707-714.
22. The Norwegian Directorate of Health. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppflgning av lungekreft [National guidelines for diagnosis and treatment of lung cancer]. Oslo, The Norwegian Directorate of Health, 2014.
23. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med 2011; 30: 377-399.
24. StataCorp. Stata statistical software: Release 13. College Station, StataCorp, 2013.
25. Pohar-Perme MP, Stare J, Esteve J. On estimation in relative survival. Biometrics 2012; 68: 113-120.
26. Brenner H, Rachet B. Hybrid analysis for up-to-date long-term survival rates in cancer registries with delayed recording of incident cases. Eur J Cancer 2004; 40: 2494-2501.
27. Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: Analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015; 385: 977-1010.
28. Aarts MJ, van den Borne BE, Biesma B, et al. Improvement in population-based survival of stage IV NSCLC due to increased use of chemotherapy. Int J Cancer 2015; 136: E387-E395.
29. Bowen EF, Anderson JR, Roddie ME. Improving surgical resection rates in lung cancer without a two stop service. Thorax 2003; 58: 368.
30. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
31. Brustugun OT, Helland A, Fjellbirkeland L, et al. Mutasjonstesting ved ikke-smcellet lungekreft [Mutation testing for non-small-cell lung cancer]. Tidsskr Nor Laegeforen 2012; 132: 952-955.
32. Sandelin M, Berglund A, Sundstrom M, et al. Patients with non-small cell lung cancer analyzed for EGFR: Adherence to guidelines, prevalence and outcome. Anticancer Res 2015; 35: 3979-3985.
33. Norwegian Radiation Protection Authority. Radiologiske undersokelser i Norge per 2008 [Radiological investigations in Norway 2008]. Oslo, Norwegian Radiation Protection Authority, 2010.
34. Hicks RJ, Kalff V, MacManus MP, et al. 18F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 2001; 42: 1596-1604.
35. Norwegian Lung Cancer Registry. rsrapport [Annual report]. Oslo, Cancer Registry of Norway, 2014.
36. Matsuo Y, Chen F, Hamaji M, et al. Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: A propensity score matching analysis. Eur J Cancer 2014; 50: 2932-2938.
37. Strom HH, Bremnes RM, Sundstrom SH, et al. Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: A randomised trial by the Norwegian Lung Cancer Study Group. Br J Cancer 2013; 109: 1467-1475.
38. Deleuran T, Thomsen RW, Norgaard M, Jacobsen JB, Rasmussen TR, Sogaard M. Comorbidity and survival of Danish lung cancer patients from 2000-2011: A population-based cohort study. Clin Epidemiol 2013; 5: Suppl. 1, 31-38.
39. Kogure Y, Ando M, Saka H, et al. Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906L. J Thorac Oncol 2013; 8: 753-758.